International Journal of Clinical Oncology

, Volume 20, Issue 2, pp 249–252 | Cite as

Treatment strategy for metastatic breast cancer with estrogen receptor-positive tumor

  • Hirotaka Iwase
Introduction to Review Articles


Metastatic breast cancer (MBC) is not a curable disease except for local recurrence or oligo-metastasis in the non-visceral organs. In fact, the 10-year survival rate after chemotherapy is approximately 5 %, and, for patients who survive, the complete response rate beyond 20 years is only 2–3 % [1, 2]. Consequently, the purpose of treatment is the prolongation of survival and the improvement of quality of life (QOL). By means of advances in treatment with the advent of a large number of new drugs, survival after recurrence has been gradually improved since the 1990s [3, 4].

Although cytotoxic chemotherapy induces severe adverse events, such as anorexia, nausea and vomiting, neurotoxicity, and hematological disorders, no clear data are available concerning the overall survival benefit compared to endocrine therapy for cases of MBC with estrogen receptor-positive (ER+) tumors [5, 6]. Endocrine therapy in breast cancer represents one of the earliest molecular-targeting...


Endocrine Therapy Human Epidermal Growth Factor Receptor Metastatic Breast Cancer Letrozole Exemestane 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Conflict of interest

The author and his immediate family members declare their conflicts of interest as follows: employment, not applicable (N/A); leadership, N/A; consultant, N/A; stock, N/A; honoraria, AstraZeneca; research funds, Chugai-Roche, AstraZeneca, Novartis, Takeda, Taiho; testimony, N/A; other, N/A.


  1. 1.
    Greenberg PA, Hortobagyi GN, Smith TL et al (1996) Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer (translated from Eng). J Clin Oncol 14(8):2197–2205 (in Eng)PubMedGoogle Scholar
  2. 2.
    Rahman ZU, Frye DK, Smith TL et al (1999) Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: a reference (translated from Eng). Cancer 85(1):104–111 (in Eng)CrossRefPubMedGoogle Scholar
  3. 3.
    Gennari A, Conte P, Rosso R et al (2005) Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies (translated from Eng). Cancer 104(8):1742–1750 (in Eng)CrossRefPubMedGoogle Scholar
  4. 4.
    Giordano SH, Buzdar AU, Smith TL et al (2004) Is breast cancer survival improving? (translated from Eng). Cancer 100(1):44–52 (in Eng)CrossRefPubMedGoogle Scholar
  5. 5.
    Fossati R, Confalonieri C, Torri V et al (1998) Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women (translated from Eng). J Clin Oncol 16(10):3439–3460 (in Eng)PubMedGoogle Scholar
  6. 6.
    Gralow JR (2005) Optimizing the treatment of metastatic breast cancer (translated from Eng). Breast Cancer Res Treat 89(Suppl 1):S9–S15 (in Eng)CrossRefPubMedGoogle Scholar
  7. 7.
    Tot T, Tabar L (2011) The role of radiological–pathological correlation in diagnosing early breast cancer: the pathologist’s perspective (translated from Eng). Virchows Arch 458(2):125–131 (in Eng)CrossRefPubMedGoogle Scholar
  8. 8.
    Lianidou ES, Mavroudis D, Georgoulias V (2013) Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer (translated from Eng). Br J Cancer 108(12):2426–2432 (in Eng)CrossRefPubMedCentralPubMedGoogle Scholar
  9. 9.
    Rothe F, Laes JF, Lambrechts D et al (2014) Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer (translated from Eng). Ann Oncol 25(10):1959–1965 (in Eng)CrossRefPubMedGoogle Scholar
  10. 10.
    Yamamoto N, Watanabe T, Katsumata N et al (1998) Construction and validation of a practical prognostic index for patients with metastatic breast cancer (translated from Eng). J Clin Oncol 16(7):2401–2408 (in Eng)PubMedGoogle Scholar
  11. 11.
    Iwase H (2008) Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer (translated from Eng). Breast Cancer 15(4):278–290 (in Eng)CrossRefPubMedGoogle Scholar
  12. 12.
    Osborne CK (1998) Tamoxifen in the treatment of breast cancer (translated from Eng). N Engl J Med 339(22):1609–1618 (in Eng)CrossRefPubMedGoogle Scholar
  13. 13.
    Howell A, Robertson JF, Abram P et al (2004) Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial (translated from Eng). J Clin Oncol 22(9):1605–1613 (in Eng)CrossRefPubMedGoogle Scholar
  14. 14.
    Di Leo A, Jerusalem G, Petruzelka L et al (2010) Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer (translated from Eng). J Clin Oncol 28(30):4594–4600 (in Eng)CrossRefPubMedGoogle Scholar
  15. 15.
    Byrne MJ, Gebski V, Forbes J et al (1997) Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian–New Zealand Breast Cancer Trials Group (translated from Eng). J Clin Oncol 15(9):3141–3148 (in Eng)PubMedGoogle Scholar
  16. 16.
    Haddow A, Watkinson JM, Paterson E et al (1944) Influence of synthetic oestrogens on advanced malignant disease (translated from Eng). Br Med J 2(4368):393–398 (in Eng)CrossRefPubMedCentralPubMedGoogle Scholar
  17. 17.
    Ellis MJ, Gao F, Dehdashti F et al (2009) Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study (translated from Eng). JAMA 302(7):774–780 (in Eng)CrossRefPubMedCentralPubMedGoogle Scholar
  18. 18.
    Iwase H, Yamamoto Y, Yamamoto-Ibusuki M et al (2013) Ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: a prospective study (translated from Eng). Br J Cancer 109(6):1537–1542 (in Eng)CrossRefPubMedCentralPubMedGoogle Scholar
  19. 19.
    Yardley DA, Noguchi S, Pritchard KI et al (2013) Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis (translated from Eng). Adv Ther 30(10):870–884 (in Eng)CrossRefPubMedCentralPubMedGoogle Scholar
  20. 20.
    Rocca A, Farolfi A, Bravaccini S et al (2014) Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer (translated from Eng). Expert Opin Pharmacother 15(3):407–420 (in Eng)CrossRefPubMedGoogle Scholar
  21. 21.
    Burzykowski T, Buyse M, Piccart-Gebhart MJ et al (2008) Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer (translated from Eng). J Clin Oncol 26(12):1987–1992 (in Eng)CrossRefPubMedGoogle Scholar
  22. 22.
    Robertson JF, Howell A, Gorbunova VA et al (2005) Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant (translated from Eng). Breast Cancer Res Treat 92(2):169–174 (in Eng)CrossRefPubMedGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2015

Authors and Affiliations

  1. 1.Department of Breast and Endocrine SurgeryKumamoto UniversityKumamotoJapan

Personalised recommendations